Soligenix Inc. (NASDAQ:SNGX) shares surged on Thursday as the company announced positive results from its Phase 2a ...

Study results support advancing SGX945 in this difficult to treat orphan disease PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company) ...

The British Society for Rheumatology and the British Association of Dermatologists developed guidelines for the management of people living with Behçet's disease.

Behçet's disease (BD) is a multisystem inflammatory disorder currently classified as a vasculitis. Its etiopathogenesis is unclear, but environmental, genetic and autoimmune factors have been ...

The SGX945 proof of concept pilot study was an open-label study that enrolled 8 patients age 18 years or older with mild to ...